Charles River Laboratories International, Inc. with ticker code (CRL) have now 12 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 280 and 205 with the average target price sitting at $249.00. Now with the previous closing price of $201.34 this is indicating there is a potential upside of 23.7%. It’s also worth noting that there is a 50 day moving average of $196.01 and the 200 day MA is $214.75. The market cap for the company is 10.35B. The stock price is currently at: 202.3 USD
The potential market cap would be $12,805,309,084 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 20.79, revenue per share of 80.34 and a 5.68% return on assets.
Charles River Laboratories International, Inc. is a full service, non-clinical contract research company. The Company provides research models required in research and development of new drugs, devices, and therapies. The Company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the research models, research model services, and research and cells solutions businesses. The DSA segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. The Manufacturing segment includes Microbial Solutions and Biologics Solutions (Biologics).
